University Hospital Gasthuisberg
Published: 4 Dec 2008
Views: 15016
Prof. Eric Van Cutsem
K-Ras mutations and FOLFIRI plus cetuximab in mCRC.
- Categories:
- Colorectal & gastro
Related Videos
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more...
Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA
4 Nov 2020
OncoAlert and ecancer weekly roundup for October 26 - 31, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
2 Nov 2020
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
28 Oct 2020
Nivolumab for oesophageal cancer following chemoradiation therapy
Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA
25 Sep 2020
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer
Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan
24 Sep 2020
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer
Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan
22 Sep 2020
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers
Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany
22 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
OncoAlert and ecancer weekly roundup for August 17-23 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
24 Aug 2020
